Jahangir Karimian1, Amir Hadi2, Makan Pourmasoumi3, Ameneh Najafgholizadeh4, Abed Ghavami5. 1. Department of General Courses, School of Management and Medical Information Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. 2. Halal Research Center of IRI, FDA, Tehran, Iran. 3. Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. 4. Department of Microbiology, Naein Branch, Islamic Azad University of Isfahan, Isfahan, Iran. 5. Department of Nutrition, School of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract
BACKGROUND AND OBJECTIVES: The impetus for the current study was to evaluate the efficacy of propolis supplementation on markers of glycemic status in adults with type 2 diabetes mellitus (T2DM). METHODS: A comprehensive search was conducted in PubMed, Scopus, Cochrane Library, Web of Science, and Google Scholar up to August 2018, identifying randomized controlled trials investigating the effect of propolis supplementation on glycemic markers in adults with T2DM. Cochrane Collaboration tool was used to evaluate the risk of bias assessment. A random-effects model was applied in the meta-analysis to compensate for potential heterogeneity among the included studies. RESULTS: Six randomized controlled trials comprising 373 participants were included in the systematic review and meta-analysis. The results of the meta-analysis revealed significant reductions in fasting plasma glucose (-13.51 mg/dl; 95% CI [-24.98, -2.04]) and hemoglobin A1C (-0.52%; 95% CI [-0.94, -0.10]) concentrations following propolis supplementation. However, no significant lowering effect was observed in fasting insulin levels (-0.53 pmol/L; 95% CI [-1.69, 0.63]) or homeostasis model assessment of insulin resistance (-0.543; 95% CI [-1.72, 0.64]). CONCLUSION: This systematic review and meta-analysis suggested that propolis supplementation may be effective in controlling glycemic levels for T2DM patients. Further studies are needed to confirm these results.
BACKGROUND AND OBJECTIVES: The impetus for the current study was to evaluate the efficacy of propolis supplementation on markers of glycemic status in adults with type 2 diabetes mellitus (T2DM). METHODS: A comprehensive search was conducted in PubMed, Scopus, Cochrane Library, Web of Science, and Google Scholar up to August 2018, identifying randomized controlled trials investigating the effect of propolis supplementation on glycemic markers in adults with T2DM. Cochrane Collaboration tool was used to evaluate the risk of bias assessment. A random-effects model was applied in the meta-analysis to compensate for potential heterogeneity among the included studies. RESULTS: Six randomized controlled trials comprising 373 participants were included in the systematic review and meta-analysis. The results of the meta-analysis revealed significant reductions in fasting plasma glucose (-13.51 mg/dl; 95% CI [-24.98, -2.04]) and hemoglobin A1C (-0.52%; 95% CI [-0.94, -0.10]) concentrations following propolis supplementation. However, no significant lowering effect was observed in fasting insulin levels (-0.53 pmol/L; 95% CI [-1.69, 0.63]) or homeostasis model assessment of insulin resistance (-0.543; 95% CI [-1.72, 0.64]). CONCLUSION: This systematic review and meta-analysis suggested that propolis supplementation may be effective in controlling glycemic levels for T2DM patients. Further studies are needed to confirm these results.